1.Guidelines of Prevention and Treatment for NSAID-related Peptic Ulcers.
Jun Haeng LEE ; Yong Chan LEE ; Seong Woo JEON ; Jeong Wook KIM ; Sang Woo LEE
The Korean Journal of Gastroenterology 2009;54(5):309-317
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used medications in Korea. Gastrointestinal toxicity, including peptic ulcer, is a common adverse effect of NSAIDs. Risk factors for NSAID-related peptic ulcer include a previous history of peptic ulcer, advanced age, high dose, concomitant use of corticosteroids, anticoagulants, other NSAIDs including low-dose aspirin. Preventive measure(s), such as COX-2 inhibitor, proton pump inhibitor or misoprostrol, should be done for patients requiring NSAID therapy who have high-risk factor(s) for peptic ulcer. Low dose aspirin also increases the risk of peptic ulcer, so preventive measure(s) should be done for high-risk patients. The eradication of Helicobacter pylori is recommended for high-risk NSAID-users. Treatment strategies for peptic ulcers in NSAID users are mostly the same for peptic ulcers in NSAID non-users.
Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
;
Anti-Ulcer Agents/therapeutic use
;
Anticoagulants/adverse effects
;
Aspirin/*adverse effects
;
Cyclooxygenase 2 Inhibitors/therapeutic use
;
Helicobacter Infections/diagnosis/drug therapy
;
Helicobacter pylori
;
Humans
;
Misoprostol/therapeutic use
;
Peptic Ulcer/drug therapy/prevention & control/*therapy
;
Proton Pump Inhibitors/therapeutic use
2.Efficacy of high-dose dual therapy for Helicobacter pylori infection eradication in servicemen: a randomized controlled trial.
Xiao Mei ZHANG ; Han Chen MIN ; Jing CHEN ; Jun Li ZHI ; Hong Xia DONG ; Jin Yan KONG ; Jiang Yun MENG ; Gang SUN ; Zi Kai WANG ; Fei PAN ; Li Hua PENG ; Yun Sheng YANG
Chinese Journal of Internal Medicine 2023;62(5):520-525
Objective: To assess the efficacy and cost-effectiveness of high-dose dual therapy compared with bismuth-containing quadruple therapy for treating Helicobacter pylori(H.pylori) infection in servicemen patients. Methods: A total of 160 H. pylori-infected, treatment-naive servicemen, including 74 men and 86 women, aged from 20 years to 74 years, with a mean (SD) age of 43 (13) years, tested in the First Center of Chinese PLA General Hospital from March 2022 to May 2022 were enrolled in this open-label, randomized controlled clinical trial. Patients were randomly allocated into 2 groups: the 14-day high-dose dual therapy group and the bismuth-containing quadruple therapy group. Eradication rates, adverse events, patient compliance, and drug costs were compared between the two groups. The t-test was used for continuous variables, and the Chi-square test for categorical variables. Results: No significant difference in H. pylori eradication rates were found between high-dose dual therapy and bismuth-containing quadruple therapy by ITT, mITT and PP analysis[ITT:90.0% (95%CI 81.2%-95.6%) vs. 87.5% (95%CI 78.2%-93.8%), χ2=0.25, P=0.617;mITT:93.5% (95%CI 85.5%-97.9%) vs. 93.3% (95%CI 85.1%-97.8%), χ2<0.01, P=1.000; PP: 93.5% (95%CI 85.5%-97.9%) vs. 94.5% (95%CI 86.6%-98.5%), χ2<0.01, P=1.000 ]. The dual therapy group exhibited significantly less overall side effects compared with the quadruple therapy group [21.8% (17/78) vs. 38.5% (30/78), χ2=5.15,P=0.023]. There were no significant differences in the compliance rates between the two groups [98.7%(77/78) vs. 94.9%(74/78), χ2=0.83,P=0.363]. The cost of medications in the dual therapy was 32.0% lower compared with that in the quadruple therapy (472.10 RMB vs. 693.94 RMB). Conclusions: The dual regimen has a favorable effect on the eradication of H. pylori infection in servicemen patients. Based on the ITT analysis, the eradication rate of the dual regimen is grade B (90%, good). Additionally, it exhibited a lower incidence of adverse events, better compliance and significantly reduced cost. The dual regimen is expected to be a new choice for the first-line treatment of H. pylori infection in servicemen but needs further evaluation.
Male
;
Humans
;
Female
;
Young Adult
;
Adult
;
Helicobacter Infections
;
Helicobacter pylori
;
Bismuth
;
Anti-Bacterial Agents/therapeutic use*
;
Amoxicillin/adverse effects*
;
Drug Therapy, Combination
;
Treatment Outcome
;
Proton Pump Inhibitors/therapeutic use*
3.Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection.
Sung Bum KIM ; Si Hyung LEE ; Kyeong Ok KIM ; Byung Ik JANG ; Tae Nyeun KIM
The Korean Journal of Gastroenterology 2015;66(5):261-267
BACKGROUND/AIMS: Ten-day sequential therapy has been evaluated as the first line therapy for Helicobacter pylori eradication but studies on sequential therapy as a second line therapy is lacking. The aim of this study was to compare the efficacy of 10-day sequential therapy and quadruple therapy as second line treatment for H. pylori eradication after failure of standard triple therapy. METHODS: Patients who did not respond to standard triple therapy for H. pylori eradication were assigned to either 10-day sequential or bismuth based quadruple therapy as second line treatment from January 2009 to December 2014 at Yeungnam University Medical Center. Post treatment H. pylori status was determined by rapid urease test, giemsa staining, or 13C-urea breath test. Eradication rate and side effects of both therapies were compared. RESULTS: A total of 158 H. pylori infected patients were included and 70 patients were treated by bismuth based quadruple therapy and 88 patients by 10-day sequential therapy. Age and sex were not significantly different between the two groups. Eradication rate was 84.3% (59/70) in quadruple group and 56.8% (50/88) in sequential group. Side effects occurred significantly higher in quadruple group than sequential group (27.1% vs. 11.4%, p=0.011). CONCLUSIONS: For second line H. pylori eradication after failure of standard triple therapy, bismuth based quadruple therapy showed significantly higher H. pylori eradication rate than 10-day sequential therapy. Further prospective studies are needed to evaluate the efficacy of 10-day sequential therapy as a second line H. pylori eradication treatment.
Adult
;
Aged
;
Aged, 80 and over
;
Anti-Bacterial Agents/adverse effects/pharmacology/*therapeutic use
;
Bismuth/adverse effects/pharmacology/*therapeutic use
;
Diarrhea/etiology
;
Drug Administration Schedule
;
Drug Therapy, Combination
;
Female
;
Helicobacter Infections/*drug therapy
;
Helicobacter pylori/drug effects
;
Humans
;
Male
;
Middle Aged
;
Proton Pump Inhibitors/adverse effects/pharmacology/therapeutic use
;
Retrospective Studies
;
Risk Factors
;
Taste Disorders/etiology
;
Treatment Outcome
;
Young Adult
4.Proton Pump Inhibitor-responsive Esophageal Eosinophilia: An Overview of Cases from One University Hospital Center.
Byungkyu AHN ; Dong Ho LEE ; Chang Min LEE ; Jae Jin HWANG ; Hyuk YOON ; Cheol Min SHIN ; Young Soo PARK ; Nayoung KIM
The Korean Journal of Gastroenterology 2016;67(4):178-182
BACKGROUND/AIMS: Eosinophilic esophagitis (EoE) is a chronic, immune/antigen-mediated esophageal disease, with eosinophilic infiltration limited to the esophagus. A minority of EoE patients respond well to proton pump inhibitor (PPI) therapy alone, and that condition is labelled PPI-responsive esophageal eosinophilia (PPI-REE). The prevalence of PPI-REE among EoE cases is unknown. We aimed to identify clinical manifestations of PPI-REE, and the proportion of PPI-REE among all EoE cases. METHODS: We reviewed pathology of the 4,075 patients who underwent esophageal biopsy at an institution from March 2003 to July 2015. EoE was diagnosed based on esophageal symptoms and eosinophilic infiltration limited to the esophagus, with ≥15 eosinophils per high-power field. We collected endoscopic and pathologic findings, and clinical features for these patients. RESULTS: Thirteen (0.3%) patients were diagnosed with EoE. Clinical manifestations were dysphagia (30.8%), foreign body sensation (23.1%), regurgitation (23.1%), cough (15.4%), heartburn (15.4%), nausea (7.7%), dyspepsia (7.7%). The endoscopic findings noted were polypoid lesion (23.1%), whitish plaque or exudate (23.1%), linear furrow (7.7%), concentric ring (7.7%), nodularity (7.7%), erosion (7.7%), and normal (30.8%). Of these patients, five had a favorable course with PPI as monotherapy. CONCLUSIONS: The proportion of EoE among all patients undergoing endoscopic biopsy was 0.3%. Of those, PPI-REE comprised 38%. Most of the endoscopic findings were atypical or normal when compared to the typical findings in EoE. In conclusion, patients who present with symptoms related to esophageal dysfunction need esophageal biopsy, regardless of the endoscopic findings. Moreover, patients diagnosed with EoE need to be treated first with PPI alone.
Adult
;
Aged
;
Endoscopy, Gastrointestinal
;
Eosinophilic Esophagitis/*diagnosis/etiology
;
Esophagus/pathology
;
Female
;
Gastroesophageal Reflux/drug therapy
;
Hospitals, University
;
Humans
;
Male
;
Middle Aged
;
Proton Pump Inhibitors/*adverse effects/therapeutic use
;
Retrospective Studies
5.Comparison on Oral versus Intravenous Proton Pump Inhibitors for Prevention of Bleeding after Endoscopic Submucosal Dissection of Gastric Lesions.
Yeoun Su JUNG ; Kyeong Ok KIM ; Si Hyung LEE ; Byung Ik JANG ; Tae Nyeun KIM
The Korean Journal of Gastroenterology 2016;67(2):74-80
BACKGROUND/AIMS: Although intravenous proton pump inhibitor (PPI) has been used for the prevention of post endoscopic submucosal dissection (ESD) bleeding, the route of administration has not been confirmed. The aim of the present study was to compare the efficacy of intravenous and oral PPI administration for the prevention of delayed post ESD bleeding. METHODS: Total 166 consecutive patients were randomly assigned to 30 mg lansoprazol twice a day (PO group) and 120 mg pantoprazole intravenous injection (IV group) for 48 hours. Finally, 65 patients in PO group and 87 patients in IV group were analyzed. After ESD, all patients underwent follow up endoscopy after 24 hours and were observed the symptoms of bleeding up to 60 days after ESD. RESULTS: Age, sex and use of anticoagulants were not different between groups. At follow up endoscopy after 24 hours, oozing and exposed vessel was noted in 4.6% of PO group and 8.0% of IV group and there was no significant difference. Delayed bleeding occurred in 4 of 65 patients (6.2%) in the PO group and 8 of 87 patients (9.2%) in the IV group (p>0.999). By multivariate analysis, oozing or exposed vessels at follow up endoscopy were risk factors for delayed bleeding (OR=17.5, p=0.022). CONCLUSIONS: There was no significant difference in the delayed bleeding, length of hospital stay according to the administration route. Bleeding stigmata at follow up endoscopy was risk factor of delayed bleeding. Oral PPI administration can cost-effectively replace IV PPI for prevention of post ESD bleeding.
2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use
;
*Administration, Oral
;
Aged
;
Anticoagulants/therapeutic use
;
Endoscopic Mucosal Resection/*adverse effects
;
Female
;
Gastroscopy
;
Humans
;
*Injections, Intravenous
;
Lansoprazole/therapeutic use
;
Male
;
Middle Aged
;
Odds Ratio
;
Postoperative Hemorrhage/etiology/*prevention & control
;
Prospective Studies
;
Proton Pump Inhibitors/*therapeutic use
;
Risk Factors
;
Stomach Neoplasms/surgery
6.Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy.
Sung Eun KIM ; Moo In PARK ; Seun Ja PARK ; Won MOON ; Youn Jung CHOI ; Ji Hyun CHEON ; Hye Jung KWON ; Ki Hwan KU ; Chang Hun YOO ; Jae Hyun KIM ; Gyu Won LEE ; Sung Eun SONG
The Korean Journal of Internal Medicine 2015;30(6):801-807
BACKGROUND/AIMS: Trends in successful eradication of Helicobacter pylori using first-line triple therapy, consisting of a proton pump inhibitor, amoxicillin, and clarithromycin, have been understudied. We evaluated H. pylori eradication rates at a single center over the last 10 years and identified risk factors related to eradication failure. METHODS: This study included 1,413 patients who were diagnosed with H. pylori infection and received 7 days of triple therapy between January 2003 and December 2012. We investigated H. pylori eradication rates retrospectively with respect to the year of therapy, as well as demographic and clinical factors. H. pylori eradication was confirmed by a 13C-urea breath test or a rapid urease test at least 4 weeks after the completion of triple therapy. RESULTS: The overall H. pylori eradication rate was 84.9%. Annual eradication rates from 2003 to 2012 were 93.5%, 80.0%, 87.2%, 88.5%, 92.0%, 88.3%, 85.7%, 84.1%, 83.7%, and 78.8%, respectively, by per-protocol analysis. The eradication rate with first-line triple therapy decreased during the last 10 years (p = 0.015). Multivariate analysis showed that female gender (odds ratio [OR], 1.69; 95% confidence interval [CI], 1.12 to 2.55) and smoking (OR, 1.61; 95% CI, 1.05 to 2.47) were associated with the failure of H. pylori eradication therapy. CONCLUSIONS: The efficacy of first-line triple therapy for H. pylori infection has decreased over the last 10 years, suggesting an increase in antibiotic-resistant H. pylori strains. Thus, other first-line therapies may be necessary for H. pylori eradication in the near future.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Amoxicillin/therapeutic use
;
Anti-Bacterial Agents/adverse effects/*therapeutic use
;
Breath Tests
;
Chi-Square Distribution
;
Clarithromycin/therapeutic use
;
Drug Resistance, Bacterial
;
Drug Therapy, Combination
;
Female
;
Helicobacter Infections/diagnosis/*drug therapy/microbiology
;
Helicobacter pylori/*drug effects
;
Humans
;
Linear Models
;
Logistic Models
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Odds Ratio
;
Proton Pump Inhibitors/adverse effects/*therapeutic use
;
Republic of Korea
;
Retrospective Studies
;
Risk Factors
;
Sex Factors
;
Smoking/adverse effects
;
Time Factors
;
Treatment Failure
;
Young Adult
7.Can proton pump inhibitors reduce rebleeding following Histoacryl sclerotherapy for gastric variceal hemorrhage?.
Ka Rham KIM ; Chung Hwan JUN ; Kyu Man CHO ; Jin Woo WI ; Seon Young PARK ; Sung Bum CHO ; Wan Sik LEE ; Chang Hwan PARK ; Young Eun JOO ; Hyun Soo KIM ; Sung Kyu CHOI ; Jong Sun REW
The Korean Journal of Internal Medicine 2015;30(5):593-601
BACKGROUND/AIMS: To evaluate the efficacy of proton pump inhibitors (PPIs) in reducing rebleeding and bleeding-related death rates after endoscopic gastric variceal obliteration (GVO) using N-butyl-2-cyanoacrylate (NBC). METHODS: This study enrolled 341 patients who were consecutively diagnosed with and treated for bleeding gastric varices. The patients were divided into PPI and non-PPI groups, and their endoscopic findings, initial hemostasis outcomes, rebleeding and bleeding-related death rates, and treatment-related complications were analyzed. RESULTS: The rate of initial hemostasis was 97.1%. rebleeding occurred in 2.2% of patients within 2 weeks, 3.9% of patients within 4 weeks, 18.9% of patients within 6 months, and 27.6% of patients within 12 months of the GVO procedure. A previous history of variceal bleeding (relative risk [RR], 1.955; 95% confidence interval [CI], 1.263 to 3.028; p = 0.003) and use of PPIs (RR, 0.554; 95% CI, 0.352 to 0.873; p = 0.011) were associated with rebleeding. Child-Pugh class C (RR, 10.914; 95% CI, 4.032 to 29.541; p < 0.001), failure of initial hemostasis (RR, 13.329; 95% CI, 2.795 to 63.556; p = 0.001), and the presence of red-colored concomitant esophageal varices (RR, 4.096; 95% CI, 1.320 to 12.713; p = 0.015) were associated with bleeding-related death. CONCLUSIONS: The prophylactic use of PPIs reduces rebleeding after GVO using NBC in patients with gastric variceal hemorrhage. However, prophylactic use of PPIs does not reduce bleeding-related death.
Adult
;
Aged
;
Aged, 80 and over
;
Chi-Square Distribution
;
Enbucrilate/*administration & dosage/adverse effects
;
Endoscopy, Gastrointestinal
;
Esophageal and Gastric Varices/complications/diagnosis/mortality/*therapy
;
Female
;
Gastrointestinal Hemorrhage/diagnosis/etiology/mortality/*therapy
;
Hemostasis, Endoscopic/adverse effects/*methods/mortality
;
Humans
;
Logistic Models
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Odds Ratio
;
Proton Pump Inhibitors/adverse effects/*therapeutic use
;
Recurrence
;
Retrospective Studies
;
Risk Factors
;
Sclerosing Solutions/*administration & dosage/adverse effects
;
Sclerotherapy/adverse effects/*methods/mortality
;
Time Factors
;
Treatment Outcome
;
Young Adult
8.Acute esophageal necrosis occurring in a patient undergoing percutaneous coronary intervention.
Hyung Jin KWON ; Sang Ho PARK ; Ji Hoon AHN ; Tae Hoon LEE ; Chang Kyun LEE
The Korean Journal of Internal Medicine 2014;29(3):379-382
Acute esophageal necrosis is uncommon in the literature. Its etiology is unknown, although cardiovascular disease, hemodynamic compromise, gastric outlet obstruction, alcohol ingestion, hypoxemia, hypercoagulable state, infection, and trauma have all been suggested as possible causes. A 67-year-old female underwent a coronary angiography (CAG) for evaluation of chest pain. CAG findings showed coronary three-vessel disease. We planned percutaneous coronary intervention (PCI). Coronary arterial dissection during the PCI led to sudden hypotension. Six hours after the index procedure, the patient experienced a large amount of hematemesis. Emergency gastrofibroscopy was performed and showed mucosal necrosis with a huge adherent blood clot in the esophagus. After conservative treatment for 3 months, the esophageal lesion was completely improved. She was diagnosed with acute esophageal necrosis. We report herein a case of acute esophageal necrosis occurring in a patient undergoing percutaneous coronary intervention.
Acute Disease
;
Aged
;
Coronary Angiography
;
Coronary Stenosis/diagnosis/physiopathology/*therapy
;
Esophageal Diseases/diagnosis/drug therapy/*etiology
;
Esophagoscopy
;
Esophagus/drug effects/*pathology
;
Female
;
Hemodynamics
;
Humans
;
Necrosis
;
Percutaneous Coronary Intervention/*adverse effects
;
Predictive Value of Tests
;
Proton Pump Inhibitors/therapeutic use
;
Risk Factors
;
Time Factors
;
Treatment Outcome
;
Ultrasonography, Interventional
;
Wound Healing